E88.3 Tumor lysis syndrome

Name of the Condition

• Tumor lysis syndrome

Summary

Tumor lysis syndrome (TLS) is a metabolic emergency characterized by rapid release of intracellular contents from dying tumor cells, leading to electrolyte imbalances, renal dysfunction, and other complications. It typically occurs after initiation of cancer treatment, particularly in rapidly proliferating or bulky tumors. The condition requires prompt recognition and management to prevent severe morbidity.

Causes

TLS results from massive tumor cell lysis, which releases nucleic acids, potassium, phosphorus, and uric acid into the bloodstream. This overwhelms the body's excretory and buffering systems, causing metabolic derangements. The syndrome is most commonly triggered by cytotoxic therapies (e.g., chemotherapy, radiation) but may also occur spontaneously in aggressive malignancies.

Risk Factors

• Rapidly proliferating tumors (e.g., acute leukemias, high-grade lymphomas)
• Large tumor burden or bulky disease
• Pre-existing renal impairment
• Dehydration or electrolyte abnormalities
• Certain chemotherapeutic agents (e.g., anthracyclines, alkylators)
• Tumor types with high cell turnover rates

Symptoms

• Nausea, vomiting, or abdominal pain
• Fatigue, weakness, or confusion
• Oliguria or decreased urine output
• Muscle cramps or tetany
• Arrhythmias or cardiac palpitations
• Signs of renal failure (e.g., elevated creatinine)

Diagnosis

Diagnosis is based on laboratory findings and clinical context. Key criteria include elevated uric acid, potassium, or phosphorus levels, along with decreased calcium. Renal function tests and electrolyte panels are essential. The Cairo-Bishop classification system stratifies TLS into laboratory (abnormal labs without symptoms) or clinical (symptomatic with organ dysfunction) categories, guiding management intensity.

Treatment Options

Management focuses on preventing or mitigating complications. Aggressive hydration with alkaline solutions helps flush uric acid and prevent crystal formation. Allopurinol or rasburicase may be used to reduce uric acid levels. Electrolyte abnormalities (e.g., hyperkalemia, hypocalcemia) require correction, often with dialysis in severe cases. Underlying malignancy treatment may be adjusted to reduce tumor burden safely.

Prognosis and Follow-Up

Prognosis depends on early intervention and severity. Untreated TLS can lead to acute renal failure or death, but prompt treatment improves outcomes. Follow-up includes monitoring electrolytes, renal function, and tumor response. Patients at high risk may require prophylactic measures during subsequent treatments. Long-term management addresses any residual organ damage.

Complications

• Acute kidney injury or renal failure
• Cardiac arrhythmias from electrolyte imbalances
• Seizures or neurological impairment
• Metabolic acidosis
• Tissue calcification from hyperphosphatemia
• Multi-organ dysfunction in severe cases

Lifestyle & Prevention

Prevention is critical for high-risk patients. Maintaining hydration before and during treatment reduces risk. Avoiding nephrotoxic agents and monitoring electrolytes closely can help. Patients should report symptoms like decreased urine output or swelling promptly. Dietary modifications (e.g., low-purine foods) may be recommended in some cases.

When to Seek Professional Help

Seek immediate medical attention for symptoms like severe nausea, confusion, chest pain, or reduced urine output during or after cancer treatment. TLS is a medical emergency requiring urgent evaluation. Even mild symptoms in high-risk patients warrant prompt assessment to prevent progression.

Tips for Medical Coders

Code E88.3 is assigned for tumor lysis syndrome. Documentation should specify whether the syndrome is laboratory or clinically evident, as this may impact coding specificity. Include details about triggering factors (e.g., treatment type) and any organ involvement. Ensure alignment with clinical guidelines to support accurate coding and reflect the severity of the condition.